{"schema":"hottub-news/list/v1","item_schema":"hottub-news/item/v1","count":3,"sponsored":0,"items":[{"id":"n_2bfvorupx73gmnvwdw6a","seq":1334030,"kind":"article","title":"Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Rating Raised to \"Strong-Buy\" at HC Wainwright","url":"https://www.themarketsdaily.com/2026/10/02/monte-rosa-therapeutics-nasdaqglue-stock-rating-raised-to-strong-buy-at-hc-wainwright.html","published":"2026-10-02T11:53:15Z","seen":"2026-10-02T11:53:15Z","lang":"en","source":{"id":"themarketsdaily.com","name":"themarketsdaily.com","domain":"themarketsdaily.com"},"via":"gdelt-gkg-english","topics":["economy","science","health","business"],"authors":["Mitch Edgeman"],"entities":[{"id":"Q115011580","name":"Monte Rosa Therapeutics","type":"org"}],"story":"st_2bfvorupx73gmnvwdw6a","category":"economy-business","category_p":0.48,"sentiment":"positive","tone":0.45,"political":0.07},{"id":"n_pkrc3gsxgflhqntprhaq","seq":1118307,"kind":"press_release","title":"Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk","url":"https://www.globenewswire.com/news-release/2026/10/01/3372740/0/en/monte-rosa-therapeutics-announces-positive-results-for-mrt-8102-in-gforce-1-phase-1-study-showing-normalization-of-key-pathogenic-drivers-of-ascvd-in-subjects-with-elevated-cvd-ris.html","summary":"Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study","published":"2026-10-01T11:00:00Z","seen":"2026-10-01T11:03:46Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","nasdaq:glue","us61225m1027"],"entities":[{"id":"Q115011580","name":"Monte Rosa Therapeutics","type":"org"},{"id":"Q1444550","name":"arteriosclerotic heart disease","type":"other"},{"id":"Q389735","name":"cardiovascular disease","type":"other"}],"story":"st_2lzhieoznxlwzptntqnq","category":"health","category_p":0.68,"sentiment":"positive","tone":0.45,"political":0.02},{"id":"n_2lzhieoznxlwzptntqnq","seq":992785,"kind":"press_release","title":"Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk","url":"https://www.globenewswire.com/news-release/2026/09/30/3372369/0/en/monte-rosa-therapeutics-to-present-results-of-mrt-8102-gforce-1-phase-1-study-in-subjects-with-elevated-cardiovascular-disease-risk.html","published":"2026-09-30T20:01:00Z","seen":"2026-09-30T20:15:36Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","nasdaq:glue","us61225m1027"],"entities":[{"id":"Q115011580","name":"Monte Rosa Therapeutics","type":"org"}],"story":"st_2lzhieoznxlwzptntqnq","category":"health","category_p":0.84,"sentiment":"neutral","tone":0.24,"political":0.03}]}